Biomedtech News
Abivax reports long-lasting two-year efficacy and safety data from ABX464 ulcerative colitis Phase 2A maintenance study
MEDEOR, Truffle Capital's new BioMedTech Fund, qualified by institutional investors through the Tibi committee
Abivax treats first patient in Phase 2B/3 ABX464 Covid-19 clinical trial
Abivax provides business update on most recent achievements and announces positive results of annual ordinary and extraordinary general meeting
Philippe Pouletty and Hartmut J. Ehrlich - ABIVAX - Covid-19 Quarantine
Investors Search for Promising Covid Cures
€ 36M non-dilutive funding from Bpifrance for ABIVAX’ ABX464 Covid-19 program
Abivax Stock Soars as French Regulator Approves Testing of a Drug to Treat Covid-19
Abivax to evaluate anti-inflammatory effects of ABX464 in large-scale COVID-19 trial
Abivax receives ANSM and Ethics Committee clearance to test its development candidate ABX464 in 1,034 Covid-19 Patients in randomized Phase 2B/3 clinical trial
